Are injectable peptides like Retatrutide safe to buy online?

Unapproved peptide products purchased online, through social media, or via personal networks have not been assessed for safety, quality, or efficacy by the Therapeutic Goods Administration. They may contain incorrect doses, impurities, or unknown substances. In 2026, six Victorians were hospitalised with acute liver toxicity after using unapproved Retatrutide formulations. The TGA has made these products a compliance enforcement priority. If you are considering a peptide product for weight loss, muscle gain, or recovery, speak with your GP first — only TGA-approved medicines have been assessed for use in Australia.

What should I tell my doctor if I have been using a peptide I bought online?

Tell your GP what product you used, where you obtained it, how you were dosing it, and how long you have been using it. Bring the packaging or product label if you have it. If you have any right upper quadrant abdominal discomfort, unusual fatigue, yellowing of the skin or eyes (jaundice), or dark urine, tell your GP immediately — these can be signs of liver injury. Your GP may order liver function tests. You will not be in trouble for disclosing this; your GP needs accurate information to assess and look after your health.

Illegal weight-loss peptides linked to liver damage in Victorian patients

What just happened

Australia’s Chief Medical Officer, Professor Michael Kidd, has issued a public health alert: six Victorians were hospitalised with acute liver toxicity in 2026 after using unapproved Retatrutide peptide products purchased online, through social media advertisements, and via personal networks.

The Therapeutic Goods Administration has designated unapproved peptide products a compliance enforcement priority for 2026. Victoria’s Chief Health Officer, Dr Caroline McElnay, has separately advised healthcare professionals to ask patients explicitly about peptide use whenever they encounter abnormal liver function or signs of acute liver injury.

This is an escalating alert, not a theoretical risk. Hospitalisations have already occurred. The products in question — marketed for weight loss, muscle growth, recovery, and anti-ageing — are being sold as though the regulatory framework simply does not apply to them. For many buyers, it is not obvious that it should.

The both-and

Why the appeal is understandable

Retatrutide is, in its legitimate pharmaceutical form, a triple agonist — acting on GLP-1, GIP, and glucagon receptors. It is in the same pharmacological class as TGA-approved medications like semaglutide (Ozempic, Wegovy) but has not yet completed regulatory approval in Australia. The preclinical and early-phase human trial results have been genuinely impressive, and those trial results have circulated widely in fitness, biohacking, and wellness communities.

When patients read about a molecule that performed well in a Phase II trial and then find it available online for a fraction of the cost of an approved GLP-1 medication, the logical gap they are being asked to bridge seems smaller than it is. The information ecosystem around performance-enhancing and weight-loss peptides is sophisticated, optimised for trust, and largely indifferent to regulatory status.

Sixty-five per cent of GPs in Australia are now reporting increased patient interest in injectable peptides. That is a majority of general practices encountering this question. The clinical conversation gap is real.

Why the regulatory gap is the critical point

Professor Kidd’s statement identifies the crux precisely: “Unapproved peptide products pose a growing public health risk. Some of these products have not undergone sufficient human clinical trials and may cause significant harm.”

Sufficient human clinical trials is doing a lot of work in that sentence. Clinical trials don’t just establish whether a drug works; they establish what happens when it is administered at specific doses, in specific formulations, in specific populations, over specific timeframes. Liver toxicity is not always predictable from the mechanism of action — it can arise from impurities, vehicle substances, formulation errors, or dose stacking. None of these variables is controlled in an unregulated supply chain.

The six Victorian patients were not doing anything unusual by their own understanding. They were using products marketed for the same goals that bring millions of people to their GPs each week: weight loss, fitness, recovery. The harm was not foreseeable to them.

My two cents

This is now a clinical vigilance issue in general practice, not just a regulatory one.

Sixty-five per cent of GPs encountering patient interest in peptides means that asking “have you been using any injectable peptides or supplements you’ve bought online?” is now a legitimate and sensible part of the history when:

A patient presents with unexplained liver function abnormalities
A patient has fatigue, right upper quadrant discomfort, or jaundice without an obvious explanation
A patient is asking about weight management or body composition and mentions peptides
A patient is managing recovery from exercise, injury, or illness and has mentioned performance supplements

Dr McElnay’s guidance is clear: ask specifically, collect product information if possible, and consider liver function testing in the right clinical context.

The information asymmetry here is significant. Many patients using these products do not know they are unapproved. Many would stop immediately if they understood the risk. The clinical conversation is the intervention — and the TGA and CMO have now provided the backing for GPs to have it directly.

RACGP clinical resources on medicines safety and the TGA framework can support these conversations when patients need more than a brief explanation during a consultation.

Verdict: yes — worth knowing about.

Sources cited

“Illegal peptide warnings intensify amid acute liver toxicity” — newsGP, 22 June 2026. https://www1.racgp.org.au/newsgp/clinical/illegal-peptide-warnings-intensify-amid-acute-live
Therapeutic Goods Administration — news and resources. https://www.tga.gov.au/news-and-resources/news
RACGP clinical resources. https://www.racgp.org.au/clinical-resources